HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Raises Price Target to $60
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and raises the price target from $50 to $60.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and raises the price target from $50 to $60.